-+ 0.00%
-+ 0.00%
-+ 0.00%

EBR Systems (ASX:EBR) Shares Trail A Revenue Surge As Losses Deepen

Simply Wall St·08/13/2026 11:34:55
Listen to the news

EBR Systems walked into this result with a bruised share price over the past three months and a market that has been sceptical of story stocks. Yet the stock sits at just A$0.30, while the company is now posting quarterly revenue above US$2.6 million and carrying a high price to sales multiple against peers. That clash between a low absolute share price and a rich revenue multiple is the real headline today. The market is trying to decide whether fast top line growth justifies the valuation or whether the recent weakness reflects deeper concern about ongoing losses.

Is EBR Systems trading like a bargain at A$0.30, or does the high P/S multiple signal a classic value trap? Compare the market price against the analyst DCF gap inside our valuation analysis for EBR Systems

Q2 2026 Earnings Summary

  • Revenue (Q2 2026 vs Q2 2025): US$2.637 million vs. US$0.170 million (very large year on year increase)
  • Net Loss (Q2 2026 vs Q2 2025): US$17.453 million loss vs. US$11.967 million loss (loss widened about 46%)
  • Basic EPS (Q2 2026 vs Q2 2025): US$0.035 loss per share vs. US$0.030 loss per share (loss per share widened about 18%)
  • Trailing Twelve Month Revenue (to Q2 2026 vs to Q2 2025): US$6.446 million vs. US$0.170 million (very large increase in annualised revenue base)

Prefer clean, visual charts instead of scrolling through dense earnings tables and PDFs? See EBR Systems' full financial picture with a clear view of its valuation story in the company report for EBR Systems.

ASX:EBR Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
ASX:EBR Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

EBR Systems revenue momentum versus growth hopes

For investors leaning positive on EBR Systems, the sharp step up in quarterly and trailing twelve month revenue aligns with a story of a cardiac device business moving further into commercial territory. The fact that sales now sit in the multi million dollar range gives the WiSE CRT concept more real world backing than a purely clinical stage pitch. For a company often discussed around trial milestones and technology potential, this revenue base gives bulls something more concrete to point to when framing growth potential.

Losses, cash burn and the cautious EBR view

The other side of the story is hard to ignore. Net loss widened from US$11.967 million to US$17.453 million and loss per share also moved higher. That fits closely with concerns about ongoing cash burn and the possibility of future capital needs if this spending pace continues. The share price is down about 47% over 90 days, which suggests the market has already been wrestling with these risks. Bears will see the larger losses as reinforcement that execution and funding remain central questions for EBR Systems.

After a 47% share price decline, widening losses and recent shareholder dilution, it is fair to ask whether EBR Systems carries deeper structural issues or only short term growing pains. Review our independent risk scores and see what other warning flags might be easy to miss inside the risk analysis for EBR Systems which shows 3 important warning signs.

Stay Ahead With Simply Wall St

If EBR Systems is now on your radar after its sharp revenue ramp and wider losses, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more attractive entry point. Once you own any stocks, keep a clear view of what matters with the Portfolio Command Center that cuts through noise and highlights key changes across your holdings. For longer term conviction, compare your thinking with thousands of other investors through the Community and see different angles on potential risks and catalysts. This way you can spot important shifts early and give yourself the best chance to stay ahead of the market.

Seeking Alternatives Beyond EBR Systems

Fresh stock ideas can move from quiet to breakout while screens are still loading. Check these under the radar lists before momentum is fully caught by the crowd and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.